Beyond Hot Flashes: The Importance of Sleep in Menopause Management

EP: 1.Understanding the Burden of Menopausal Vasomotor Symptoms

EP: 2.Barriers to VMS Treatment and Impact on Long-Term Health

EP: 3.Improving Access and Equity in VMS Treatment

EP: 4.Integrating VMS Treatment Into Comprehensive Women’s Health Management

EP: 5.Advances in Menopause Treatment: A Focus on the Neurokinin Pathway

EP: 6.Fezolinetant in Focus: Key Findings From the SKYLIGHT Trials

EP: 7.Elinzanetant and the OASIS Trials: Quality of Life and Symptom Relief

EP: 8.Safety Profiles of Neurokinin-Targeted Therapies for VMS

Now Viewing

EP: 9.Beyond Hot Flashes: The Importance of Sleep in Menopause Management

EP: 10.Closing Thoughts: Evolving Treatment Paradigms in Menopause Management

Video content above is prompted by the following:

1. (PINKERTON) Sleep has been identified as an independent symptom from hot flashes. With the emerging research regarding the use of elinzanetant to combat sleep disturbances associated with menopause [such as anticipated data from the NIRVANA trial], how important is it to address sleep as part of menopause management, even in the absence of vasomotor symptoms, and how is sleep quality linked to other complications such as mood disorders, cardiovascular disease, and Alzheimer disease?
   1. What role do you anticipate elinzanetant to have in this space?
2. (FIFFICK) How do you anticipate the treatment paradigm of VMS associated with menopause to shift with the advent of these new neurokinin-targeted therapies?
   1. Please discuss your thoughts on whether they’ll become a new standard of care, and if you anticipate them being used as monotherapy vs combination therapy.